Amicus (FOLD) AI Stock Analysis

• Market Cap: $2.15B
• Dividend Yield: N/A
• Average Volume (3M): 4.16M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.63
• Revenue Growth: 25.35%
• EPS Growth: 69.35%
• Country: US
• Employees: 499
• Sector: Healthcare
• Sector Strength: 43
• Industry: Biotechnology
• EPS (TTM): -0.08
• Shares Outstanding: 308,239,380
• 10 Day Avg. Volume: 5,164,603
• 30 Day Avg. Volume: 4,163,332
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: 0.92
• Enterprise Value/Revenue: 3.64
• Enterprise Value/Gross Profit: 4.00
• Enterprise Value/Ebitda: 36.89
• 1Y Price Target: $14.79
• Price Target Upside: 107.72% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 8

• Rating: 60 Neutral
• Price Target: $6.50 ▼(-8.71% Downside)

Amicus Therapeutics scores moderately due to its strong revenue growth and strategic outlook, as highlighted in the earnings call. However, financial instability from net losses and high debt, along with valuation concerns, weigh down the score.

Positive Factors

Pipeline Development

The newly expanded rare disease pipeline with DMX-200 for FSGS is on track for full enrollment, offering pipeline optionality.

Product Launches

Pombiliti+Opfolda launch is starting to gain traction with strong new patient starts across various global launches.

Revenue Growth

Amicus reported strong revenue growth and continued momentum in its core Pompe and Fabry disease franchises, positioning the company for GAAP profitability.

Negative Factors

Competitive Pressure

Taking meaningful market share away from Sanofi's ERTs will remain a challenge.

Financial Challenges

FOLD reported a 2Q25 GAAP net loss of $24.4M, with an EPS of ($0.08), highlighting ongoing financial challenges.

Revenue Guidance

FY25 total revenue guidance was lowered from +17-24% at CER to +15-22% at CER due to an unexpectedly higher UK VPAG rebate rate.

Amicus Business Overview & Revenue Model

Company Description

Amicus Therapeutics, Inc. (FOLD) is a biopharmaceutical company focused on developing innovative therapies for rare and devastating diseases, particularly those caused by genetic mutations. The company operates primarily in the biotechnology sector, concentrating on the development of treatments for lysosomal storage disorders, including Fabry disease and Pompe disease. Amicus is known for its proprietary enzyme replacement therapies and small molecule pharmacological chaperones, which are designed to improve patient outcomes and quality of life.

How the Company Makes Money

Amicus Therapeutics generates revenue primarily through the development and commercialization of its pharmaceutical products. The company earns money by selling its approved therapies directly to healthcare providers and through partnerships with larger pharmaceutical companies that may involve co-development or licensing agreements. Key revenue streams include sales of its lead products, such as Galafold (migalastat) for Fabry disease, which has been approved in various markets. Additionally, Amicus may receive milestone payments and royalties from collaborations with partners, contributing to its overall financial performance. The company's ability to secure reimbursement agreements with insurance providers and government healthcare programs also plays a critical role in its revenue generation.

Amicus Financial Statement Overview

Summary

Amicus exhibits strong revenue growth and gross profit margins. However, persistent net losses and high debt levels indicate financial instability, with challenges in achieving profitability and maintaining financial flexibility.

Income Statement

The company shows a positive revenue growth trend with a TTM (Trailing-Twelve-Months) revenue of $543.1 million, up from $528.3 million in the previous annual period. Gross profit margin remains strong at approximately 91%. However, the net profit margin is negative due to consistent net losses, indicating profitability challenges. EBIT and EBITDA margins have improved but remain low, suggesting limited operational efficiency.

Balance Sheet

The company's debt-to-equity ratio is relatively high, indicating significant leverage, which could pose a financial risk. The equity ratio stands at 24.5%, showing a moderate proportion of equity financing. The return on equity is negative due to net losses, highlighting the company's struggle to generate returns for shareholders.

Cash Flow

The free cash flow has turned positive in the TTM period, showing improvement from the previous annual period. The operating cash flow to net income ratio is positive, indicating some level of cash generation from operations. However, the free cash flow to net income ratio remains low, pointing to challenges in converting earnings into cash flow.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	543.14M	528.29M	399.36M	329.23M	305.51M	260.89M
Gross Profit	494.22M	475.35M	362.03M	290.63M	271.05M	229.84M
EBITDA	53.63M	29.39M	-92.08M	-199.58M	-202.87M	-242.98M
Net Income	-29.37M	-56.11M	-151.58M	-236.57M	-250.46M	-276.85M
Balance Sheet
Total Assets	789.84M	785.03M	777.88M	724.17M	905.14M	886.52M
Cash, Cash Equivalents and Short-Term Investments	250.57M	249.95M	286.20M	293.60M	482.50M	483.27M
Total Debt	443.47M	443.64M	445.06M	452.12M	440.13M	441.73M
Total Liabilities	596.28M	590.99M	617.71M	601.12M	597.77M	600.14M
Stockholders Equity	193.56M	194.04M	160.17M	123.05M	307.37M	286.38M
Cash Flow
Free Cash Flow	1.61M	-37.44M	-76.53M	-170.34M	-206.38M	-236.52M
Operating Cash Flow	3.56M	-33.89M	-69.09M	-166.57M	-202.49M	-233.29M
Investing Cash Flow	-40.96M	-560.00K	98.06M	92.32M	78.76M	-13.58M
Financing Cash Flow	6.73M	5.12M	61.68M	-7.46M	212.07M	262.86M

Amicus Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 7.12
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FOLD, the sentiment is Positive. The current price of 7.12 is above the 20-day moving average (MA) of 6.49, above the 50-day MA of 6.19, and below the 200-day MA of 8.14, indicating a neutral trend. The MACD of 0.25 indicates Negative momentum. The RSI at 65.00 is Neutral, neither overbought nor oversold. The STOCH value of 88.14 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for FOLD.

Amicus Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
FOLD	60 Neutral	$2.15B	―	-22.62%	―	25.35%	69.35%
APLS	58 Neutral	$3.49B	―	-108.49%	―	20.02%	33.45%
Sector *	51 Neutral	$7.44B	-0.20	-46.00%	2.26%	22.80%	-2.27%
SRRK	50 Neutral	$3.10B	―	-172.08%	―	―	-29.50%
RARE	49 Neutral	$2.80B	―	-182.60%	―	26.77%	24.18%
CRNX	49 Neutral	$2.80B	―	-36.94%	―	―	-9.10%
IMVT	45 Neutral	$2.65B	―	-77.58%	―	―	-48.38%

Amicus Corporate Events

Amicus Stockholders Approve Directors and Equity Plan

At the 2025 Annual Meeting of Stockholders held on June 5, 2025, Amicus‘s stockholders elected four Class III directors for a three-year term and approved the 2025 Equity Incentive Plan. They also ratified Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025, and approved the executive compensation on an advisory basis.

The most recent analyst rating on (FOLD) stock is a Buy with a $20.00 price target. To see the full list of analyst forecasts on Amicus stock, see the FOLD Stock Forecast page.